AUROPHARMA vs WOCKPHARMA: Stock Comparison

Aurobindo Pharma Limited vs Wockhardt Ltd

Live data: 22 July 2026, 1:29 PM IST • Source: NSE and company filings

Aurobindo Pharma Limited is the larger company by market capitalisation. Aurobindo Pharma Limited shows a lower P/E, a higher ROE and a higher dividend yield, while Wockhardt Ltd shows faster revenue growth. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Side-by-side comparison of Aurobindo Pharma Limited and Wockhardt Ltd on live price, valuation, growth, profitability, leverage and quarterly shareholding. Highlighted values mark the more favourable of the two on that metric's usual reading; a single metric is never the full story.

On standard readings, AUROPHARMA is more favourable on 10 of 13 scored metrics and WOCKPHARMA on 3These counts are context-free and are not an overall rating.

Key Differences

Market Cap
AUROPHARMA is the larger company
₹88,263 Cr vs ₹30,337 Cr
P/E Ratio
AUROPHARMA has a lower P/E
26.03x vs 144.46x
P/B Ratio
AUROPHARMA has a lower P/B
2.41x vs 6.23x
EPS
AUROPHARMA has higher earnings per share
₹60.36 vs ₹13.1
Dividend Yield
AUROPHARMA has a higher dividend yield
0.26% vs 0%
Revenue Growth (TTM YoY)
WOCKPHARMA has faster revenue growth
26% vs 5.6%
EPS Growth (TTM YoY)
AUROPHARMA has faster EPS growth
1.9% vs 0%
Qtr Sales Growth
WOCKPHARMA has stronger quarterly sales growth
29.9% vs 5.62%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricAUROPHARMAWOCKPHARMA
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricAUROPHARMAWOCKPHARMA
Live Price₹1,533.1₹1,867.5
Day Change-2.95%-1.52%
Volume15.31 L6.04 L
52-Week High₹1,636.8₹2,422.3
52-Week Low₹1,016.1₹1,086.7
Distance from 52W High-6.34%-22.9%

Valuation

MetricAUROPHARMAWOCKPHARMA
Market Cap₹88,263 Cr₹30,337 Cr
P/E Ratio26.03x144.46x
P/B Ratio2.41x6.23x
EPS₹60.36₹13.1
Book Value₹652.31₹304
Dividend Yield0.26%0%

Growth

MetricAUROPHARMAWOCKPHARMA
Revenue Growth (TTM YoY)5.6%26%
EPS Growth (TTM YoY)1.9%0%
Qtr Sales Growth5.62%29.9%
Qtr Profit Growth1.97%688%

Profitability & Leverage

MetricAUROPHARMAWOCKPHARMA
ROE10.1%6.11%
ROCE12.8%7.55%
Net Margin10.62%3.3%
Operating Margin20.3%19.3%
Debt to Equity0.21x0.45x

Shareholding

As of Jun 2026 • change vs previous quarter
MetricAUROPHARMAWOCKPHARMA
Promoter Holding48.81% 0.06 pp49.08%
FII Holding16.38% 1.14 pp7.09% 0.1 pp
DII Holding25.1% 0.77 pp10.96% 0.41 pp
Public Holding6.64% 0.44 pp32.83% 0.52 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: Aurobindo Pharma Limited and Wockhardt Ltd.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.